Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CANbridge Appoints SVP, Rare Disease Commercial Operations | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

CANbridge Appoints SVP, Rare Disease Commercial Operations

Marcelo Cheresky brings nearly 20 years' business leadership experience in the biotechnology industry

By: Cassandra Gervolino

CANbridge Pharmaceuticals Inc. has appointed Marcelo Cheresky to the position of Senior Vice President, Rare Disease Commercial Operations, effective as of July 16, 2019.
 
Mr. Cheresky has nearly 20 years’ business leadership experience in the biotechnology industry. Most recently, he was Vice President, Emerging Markets at Bioverativ, a Sanofi company, in Boston, MA, where he established regional structures for emerging markets and oversaw country launches in multiple emerging markets, including Australia, Columbia and Taiwan.  
 
“We are very pleased to have a leader of such high-caliber experience heading up the CANbridge rare disease commercial team as we submit the first CANbridge rare disease NDA, for Hunterase, in China,” said James Xue, PhD, Founder, Chairman and CEO, CANbridge Pharmaceuticals. “Marcelo’s strong international experience, particularly in emerging markets, proven commercial strategy success and sophisticated grasp of the nuances of managing a global pharmaceutical enterprise, will put CANbridge in good stead as we build our RD pipeline targeting China and other international markets.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters